source
- Intellia's single-dose CRISPR therapy cuts hereditary angioedema attacks in Phase 3 trialIntellia Therapeutics reported that its gene-editing candidate lonvo-z produced a dramatic reduction in swelling attacks for patients with hereditary angioedema in a Phase 3 study. The single-dose…
- Intellia's in-body CRISPR therapy achieves first Phase 3 successIntellia announced that its experimental in vivo CRISPR gene‑editing therapy has completed a Phase 3 trial with positive results. This is the first instance of a CRISPR‑based treatment delivered d…